NCT06793709View on ClinicalTrials.gov

A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy

RecruitingOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

July 10, 2025

Primary Completion Date

November 12, 2030

Study Completion Date

November 12, 2030

Conditions
Biliary Tract Cancer
Interventions
OTHER

No Intervention

This is a non-interventional study.

Trial Locations (1)

Unknown

RECRUITING

#Eisai Trial Site 1, Tokyo

All Listed Sponsors
lead

Eisai Co., Ltd.

INDUSTRY